Tested Applications
| Positive WB detected in | fetal human brain tissue, human spleen tissue |
| Positive IHC detected in | human tonsillitis tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:4000 |
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
66282-1-Ig targets CD200 in WB, IHC, IF, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human |
| Host / Isotype | Mouse / IgG1 |
| Class | Monoclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag5045 Product name: Recombinant human CD200 protein Source: e coli.-derived, PET28a Tag: 6*His Domain: 1-269 aa of BC022522 Sequence: MERLVIRMPFCHLSTYSLVWVMAAVVLCTAQVQVVTQDEREQLYTPASLKCSLQNAQEALIVTWQKKKAVSPENMVTFSENHGVVIQPAYKDKINITQLGLQNSTITFWNITLEDEGCYMCLFNTFGFGKISGTACLTVYVQPIVSLHYKFSEDHLNITCSATARPAPMVFWKVPRSGIENSTVTLSHPNGTTSVTSILHIKDPKNQVGKEVICQVLHLGTVTDFKQTVNKGYWFSVPLLLSIVSLVILLVLISILLYWKRHRNQDREP Predict reactive species |
| Full Name | CD200 molecule |
| Calculated Molecular Weight | 269 aa, 30 kDa |
| Observed Molecular Weight | 40-50 kDa |
| GenBank Accession Number | BC022522 |
| Gene Symbol | CD200 |
| Gene ID (NCBI) | 4345 |
| RRID | AB_2881665 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Protein G purification |
| UNIPROT ID | P41217 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
CD200, also known as OX2, is a type I transmembrane glycoprotein that belongs to the immunoglobulin superfamily (PMID: 3032785). It contains two extracellular immunoglobulin domains, a transmembrane and a cytoplasmic domain. CD200 is expressed on a variety of cell types, including thymocytes, B lymphocytes, a subset of T lymphocytes, follicular dendritic cells, neurons, and endothelial cells (PMID: 3032785; 10981966). CD200 binds to its receptor, CD200R, which is primarily expressed by myeloid and T cell lineage (PMID: 15187158). The CD200-CD200R interaction plays a role in immunosuppression and suppression of anti-tumor immune responses (PMID: 22020332).
Protocols
| Product Specific Protocols | |
|---|---|
| IHC protocol for CD200 antibody 66282-1-Ig | Download protocol |
| WB protocol for CD200 antibody 66282-1-Ig | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The anti-CD200 antibody (Cat# 66282-1-Ig) has 6 total citations published in Cell Reports, Oncoimmunology, Scientific Reports, Cancers (Basel), Human Mutation, and Pediatric Surgery International. Research fields span cancer immunology and oncology, including non-small cell lung cancer, pancreatic cancer, clear cell renal cell carcinoma, and neuroblastoma, with applications in IF, WB, and IHC for studying CD200's role in tumor microenvironment and prognosis.
| Species | Application | Title |
|---|---|---|
Oncoimmunology CD200 and CD200R1 are differentially expressed and have differential prognostic roles in non-small cell lung cancer.
| ||
Sci Rep CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors.
| ||
Cancers (Basel) Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic Cancer. | ||
Pediatr Surg Int CD200 expression predicts poor prognosis in neuroblastoma: a potential biomarker for treatment stratification-a retrospective cohort study.
| ||
Hum Mutat A Tertiary Lymphoid Structure-Derived Prognostic Signature Integrates Immune Microenvironment and Mutational Landscapes in Clear Cell Renal Cell Carcinoma. |
